Key Insights

Highlights

Success Rate

77% trial completion

Published Results

15 trials with published results (38%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 47/100

Termination Rate

17.5%

7 terminated out of 40 trials

Success Rate

76.7%

-9.8% vs benchmark

Late-Stage Pipeline

3%

1 trials in Phase 3/4

Results Transparency

65%

15 of 23 completed with results

Key Signals

15 with results77% success

Data Visualizations

Phase Distribution

39Total
Not Applicable (13)
Early P 1 (1)
P 1 (8)
P 2 (16)
P 3 (1)

Trial Status

Completed23
Terminated7
Active Not Recruiting5
Withdrawn4
Recruiting1

Trial Success Rate

76.7%

Benchmark: 86.5%

Based on 23 completed trials

Clinical Trials (40)

Showing 20 of 20 trials
NCT03880422Not ApplicableRecruiting

Nutrition and Exercise Interventions for Androgen Deprivation Therapy-Induced Obese Frailty in Elderly and Non-Elderly Survivors of Advanced Prostate Cancer

NCT02346253Not ApplicableActive Not Recruiting

High-Dose Brachytherapy in Treating Patients With Prostate Cancer

NCT01923506Phase 1Active Not Recruiting

Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer After Undergoing Surgery

NCT01655836Phase 1Active Not Recruiting

High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer

NCT01823562Phase 1Active Not Recruiting

Aborption and Metabolism of Lyophilized Black Raspberry Food Products in Men With Prostate Cancer Undergoing Surgery

NCT02176902Not ApplicableActive Not Recruiting

Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate Cancer

NCT03103321Phase 3Completed

Decision Aids in Improving Knowledge in Patients With Newly Diagnosed Prostate Cancer

NCT02163317Not ApplicableCompleted

Magnetic Resonance Guided Focal Stereotactic Body Radiation Therapy for Localized Prostate Cancer

NCT01555632Not ApplicableWithdrawn

Atorvastatin Calcium in Preventing Metabolic Syndrome in Prostate Cancer Patients Receiving Androgen-Deprivation Therapy

NCT02420652Phase 2Terminated

Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate Cancer That Has Progressed After Surgery or Radiation Therapy

NCT02217709Phase 2Completed

Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer

NCT03233555Not ApplicableCompleted

Extended Cancer Education for Longer-Term Survivors in Primary Care for Patients With Stage I-II Breast or Prostate Cancer or Stage I-III Colorectal Cancer

NCT03122743Completed

Collection of Serum Samples in Studying Emotional Stress in Patients With Prostate Cancer

NCT02250014Phase 1Completed

The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate Cancer

NCT02767921Phase 1Terminated

sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer

NCT01912820Phase 1Completed

Effect of Quercetin on Green Tea Polyphenol Uptake in Prostate Tissue From Patients With Prostate Cancer Undergoing Surgery

NCT01882985Phase 2Completed

Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer Patients

NCT01928485Phase 2Terminated

Green Tea Extract in Treating Patients With Low-Risk Prostate Cancer

NCT01859689Phase 2Withdrawn

Internal Radiation Therapy in Treating Patients With Low-Risk Prostate Cancer

NCT01664130Not ApplicableCompleted

High-Dose Stereotactic Radiation for Prostate Cancer

Scroll to load more

Research Network

Activity Timeline